# VERITAC-3 (NCT05909397)

> Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05909397
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Breast Cancer
- Interventions: Vepdegestrant (ARV-471/PF-07850327); Palbociclib; Letrozole; Palbociclib
- Enrollment: 59
- Primary outcome: Study Lead-in (SLI): Incidence of Grade 4 neutropenia
- Primary outcome: SLI: Incidence of dose reduction
- Primary outcome: SLI: Incidence of drug discontinuation.
- Primary outcome: Phase 3: Progression-Free Survival

## Commentary we found

- Podcasts: 5
- YouTube: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=veritac-3-nct05909397

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05909397", "email": "<work email>"}; the inbox owner confirms by the emailed link.